What are the contraindications of Entereg (alvimopan)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules [see Warnings and Precautions ( 5.3)] . The contraindications of Entereg (alvimopan) are:

  • Patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules 1 1

From the Research

Entereg (alvimopan) is contraindicated in patients with severe hepatic impairment, end-stage renal disease, those who have used therapeutic doses of opioids for more than 7 consecutive days immediately before starting Entereg, and patients with known hypersensitivity to the drug or any of its components. The medication should not be used in patients who have had a complete gastrointestinal obstruction or patients who have had surgery for correction of complete bowel obstruction, as well as those who have had recent gastric, small, or large bowel resection 2. The contraindications of Entereg are due to its mechanism of action as a peripherally acting mu-opioid receptor antagonist, which can precipitate withdrawal in opioid-dependent patients and may interfere with healing after certain gastrointestinal surgeries 3. Some key points to consider when prescribing Entereg include:

  • Severe hepatic impairment: Entereg is contraindicated in patients with severe hepatic impairment due to the potential for increased risk of adverse effects 4.
  • End-stage renal disease: Patients with end-stage renal disease should not receive Entereg due to the potential for increased risk of adverse effects 5.
  • Recent opioid use: Patients who have used therapeutic doses of opioids for more than 7 consecutive days immediately before starting Entereg should not receive this medication due to the risk of precipitating withdrawal 6.
  • Gastrointestinal obstruction or surgery: Entereg should not be used in patients who have had a complete gastrointestinal obstruction or patients who have had surgery for correction of complete bowel obstruction, as well as those who have had recent gastric, small, or large bowel resection 2.
  • Hypersensitivity: Entereg is contraindicated in patients with known hypersensitivity to the drug or any of its components 3. It is essential to carefully evaluate the patient's medical history and current condition before prescribing Entereg to ensure safe and effective use of the medication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.